Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > XGN Exagen > Detailed Quotes

XGN Exagen

Watchlist
5.700
+0.090+1.60%
Trading Session 06/30 14:42 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
5.725
Open
5.490
Turnover
190.96K
Low
5.260
Pre Close
5.610
Volume
34.10K
Market Cap
92.66M
P/E(TTM)
Loss
52wk High
15.130
Shares
16.26M
P/E(Static)
Loss
52wk Low
4.150
Float Cap
43.01M
Bid/Ask %
0.00%
Historical High
29.858
Shs Float
7.55M
Volume Ratio
0.16
Historical Low
4.150
Dividend TTM
--
Div Yield TTM
--
P/B
1.22
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.45%
Amplitude
8.29%
Avg Price
5.599
Lot Size
1
Float Cap
43.01M
Bid/Ask %
0.00%
Historical High
29.858
Shs Float
7.55M
Volume Ratio
0.16
Historical Low
4.150
Dividend TTM
--
P/B
1.22
Dividend LFY
--
Turnover Ratio
0.45%
Amplitude
8.29%
Avg Price
5.599
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient’s blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
CEO: Rocca, Fortunato Ron
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top